Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 5Squamous Cell Carcinoma of Head and Neck 3Oropharyngeal Neoplasms 2Adenocarcinoma 2Stomatitis 1Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7 1Recurrence 1Prostate Adenocarcinoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Malignant Liver Neoplasm 1Lung Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Eyelid Squamous Cell Carcinoma 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma 1Breast Neoplasms 1

Interventions

relugolix 2acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 2Specimen Handling 2Radiotherapy 2Radiation 2Magnetic Resonance Spectroscopy 2Leuprolide 2Goserelin 2Biopsy 2radium Ra 223 dichloride 1luprolide acetate gel depot 1histrelin 1gallium 68 PSMA-11 1enzalutamide 1darolutamide 1bicalutamide 1Triptorelin Pamoate 1Surgical Procedures, Operative 1Salicylic Acid 1Radiotherapy, Image-Guided 1Radiosurgery 1Radiation Dose Hypofractionation 1Flutamide 1Buserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Prostate Adenocarcinoma × Radiotherapy, Image-Guided × 90 days × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡